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Important paradigms of pulmonary disease with nontuberculous mycobacteria (NTM) are currently shifting based
on an increasing attention within the field of cystic fibrosis (CF). These shifts are likely to benefit the management
of all patients with pulmonary NTM, regardless of underlying pathology. Currently several key areas are being
revised: The first outbreak of human NTM transmission has been proven and new evidence of biofilm growth
in vivo has been demonstrated. A better understanding of the clinical impact of NTM infection has led to increased
diagnostic vigilance and new recommendations for lung transplantation are under way. While recent changes have
reinvigorated the interest in NTM disease, the challenge remains, whether such advances can be successfully
translated into improved management and care.
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Announced as the most important emerging threat to
cystic fibrosis (CF) patients at the 2013 European Cystic
Fibrosis Conference, the perception of nontuberculous
mycobacteria (NTM) disease has once again undergone
a notable shift. Previously thought of as a group of ra-
ther benign environmental bacteria associated with ran-
dom colonization and only rarely with genuine infection
of the airway [1], perceptions have now changed. Myco-
bacterium abscessus Complex (MABSC) and Mycobac-
terium avium Complex (MAC) are now recognized as
insidious opportunists that can seriously affect morbidity
and mortality in CF. Fundamental paradigms of NTM
pulmonary disease concerning clinical impact, patient
susceptibility, transmission, bacterial modes of growth
and implications for lung transplantation are currently
being revised. Such issues are not unique to CF and can
be expected to affect NTM management in patients with
other underlying pulmonary diseases. While great leaps
have been made in understanding the scope and impact
of NTM infections, advances in diagnostics and anti-
biotic management have been less impressive and still* Correspondence: tavs.qvist@gmail.com
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ease is now receiving. Since 2007, the American Thor-
acic Society (ATS)’s and the Infectious Disease Society of
America (IDSA)’s comprehensive statement on NTM
disease has been the principle guide of management [2].
2014 appears to be the year where the eagerly expected
CF specific NTM guidelines will be published, hopefully
building further consensus in a field void of solid empir-
ical evidence and highlighting areas in urgent need of
attention.Biofilm growth
New evidence that rapidly growing NTM can grow
in vivo as biofilms on intravascular catheters [3] could
be an indication that biofilm growth in pulmonary NTM
disease might also be a concern. Emerging evidence that
pulmonary Mycobacterium tuberculosis (TB) is a biofilm
infection [4] and our group’s recent examination of
explanted CF lungs from patients with MABSC [5], sug-
gests that this might indeed be the case. MABSC has
been shown to be capable of structured cord formation,
a biofilm mode of growth, associated with the morpho-
logically distinct rough growth pattern [6,7]. This pattern
is assumed to be similar to that proven for TB [8], suggest-
ing that biofilm formation, is an inherent part of NTM
pathogenesis in pulmonary disease. While phenotyped. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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linked to increased virulence [9], data on the genetic de-
terminants of cord formation remain sparse. Future strat-
egies might include using transposons for insertional
mutagenesis [10], experimental lung models and sequen-
tial sequencing [11]. Addressing whether in vivo biofilm
growth takes place in the CF lung could prove pivotal in
explaining the notorious unreliability of in vitro suscepti-
bility testing. The discrepancy between in vitro antibiotic
resistance and the clinical benefit of treatment suggests
that more than just antibiotic resistance is involved and
that antibiotic tolerance, inferred by a protective biofilm
coat could be present, in parallel with what is observed in
other chronic infections [12,13]. Demonstrating NTM bio-
film growth in the human lung could also open up new
treatment opportunities as biofilm disrupting targets could
be systematically examined, something that has not previ-
ously been attempted for NTM.
Diagnostic challenges and opportunities
Identifying patients with NTM and clinical deterioration
is difficult, but important, as these are the once most
likely to benefit from antimycobacterial treatment. While
conventional culture and acid-fast microscopy remain the
backbone of mycobacterial diagnostics, some changes are
under way, which could affect both the sensitivity and spe-
cificity of NTM diagnostics. New recommendations on
NTM diagnostics are likely to include shorter time from
sampling to culture, increased focus on routine screening,
centralization of testing to larger mycobacteriological ref-
erence laboratories and validated pretreatment of samples
to avoid Gram negative bacterial or fungal overgrowth.
Several of these principles are already recommended, but
not universally implemented [2]. MABSC, also called
Mycobacterium abscessus sensu lato comprises the closely
related species Mycobacterium asbcessus sensu stricto,
Mycobacterium massiliense and Mycobacterium bolletii.
Differentiation of the MABSC subspecies is difficult [14],
and most clinical laboratories report infection with any of
the three merely as M. abscessus. Historical variability in
NTM taxonomy has only added to the confusion of how
to correctly classify members of MABSC and MAC. Ad-
vances in molecular diagnostics and whole genome se-
quencing in particular, promise a brighter future for
speciation, which is important in light of new insights into
differences in virulence between subspecies. Importantly
the subspecies M. massiliense remains susceptible to
macrolides even after prolonged exposure, resulting from
an inactivating erm (41) deletion [15]. Finally, immuno-
logical assays could prove useful as a means of monitoring
NTM disease progression in a fashion similar to assays
used in Pseudomonas aeruginosa infections in CF [16,17].
Thus, assays utilizing MABSC antigens-to-patient serum
IgG have been shown to correlate with clinical disease[18,19] and are currently being explored further for clin-
ical use [20].
Prevalence and clinical impact
Reported prevalence rates have varied over time and
geographically and are summarized in Table 1.
Generally there has been a tendency towards higher
prevalence rates being reported over time with a median
prevalence rate of 9% (IQR: 3 – 11%) in the 9 studies
initiated before 2000 and 13% (IQR: 7 – 17%) for the 10
post millennium prevalence studies. The reasons for this
possible rise in NTM prevalence remain unknown, but
could include changes in surveillance strategies although
many centers are adamant that is not the case. Other
reasons could include greater exposure [38], changes in
the lung flora due to inhaled antibiotics [39], and re-
duced host immunity through autophagy inhibition dur-
ing azithromycin treatment [40] or patient-to-patient
transmission [15].
North American studies have consistently reported a
higher proportion of MAC compared to MABSC [41],
whereas the opposite is true for Western European
studies [42], but the reasons for these geographical dif-
ferences remain elusive. Another trend with some
consistency, is that MABSC species, while isolated at all
ages, seem to peak in prevalence in children, while MAC
reaches the highest prevalence among adults [30,43,44], al-
though this paradigm has been challenged [41]. Catherinot
et al. have proposed that patient susceptibility might play
a bigger role than previously thought, specifically pointing
to an association between MABSC and more severe
forms of CF [43]. Improved epidemiological surveillance
such as the recent inclusion of NTM microbiology in the
European CF registry will certainly be helpful in designing
studies with the size required to address these questions.
While chronic MAC is not considered a critical threat
to patient health, isolation of MABSC is often a real
cause for concern. Some patients are diagnosed early on
a routine mycobacterial culture, suggesting an initial
phase of low to no clinical impact, which predates later
loss of lung function [45]. Others develop chronic
MABSC infection which can cause severe, sometimes
fatal lung disease, even after an indolent period of sev-
eral years [46]. A 2010 study from the US found that
those infected with MABSC had a more rapid decline in
lung function than their uninfected counterparts (3% per
year vs. 2% per year) [29]. While the association with
poor lung function is well established, the question of
whether infection is mostly a consequence of, or a pre-
disposing factor for poor lung function, remains un-
answered. A 2014 study suggests that the rate of decline
in FEV1 in the year leading up to the first positive cul-
ture may help distinguish patients who progress to active
NTM disease and require treatment [41]. This study also
Table 1 Studies reporting the prevalence of nontuberculous mycobacteria in cystic fibrosis populations
Study Study year Location Design Included CF patients NTM cases NTM revalence % MABSC % MAC
Boxerbaum B. 1980 OH, USA Prospective 430 8 1.8 75* 0
Smith MJ et al. [21] 1984 UK Prospective 223 4 1.8 25* 0
Hjelte L et al. [22] 1990 Sweden Prospective 54 5 9.2 0 60
Kilby JM et al. [23] 1992 NC, USA Prospective 87 17 19.5 29* 76
Aitken ML et al. [24] 1993 WA, USA Prospective 64 8 12.5 0 88
Hjelt K et al. [25] 1994 Denmark Prospective 185 7 3.8 71* 29
Sermet-Gaudelus I et al. [26] 1996-99 France Prospective 296 29 9.8 52 21
Fauroux B et al. [27] 1997 France Prospective 106 7 6.6 43* 0
Mussaffi H et al. [28] 1997-02 Israel Retrospective 139 12 8.6 67§ 25§
Esther CR Jr et al. [29] 2000-07 NC, USA Registry 1,216 166 13.7 41 59
Pierre-Audigier C et al. [30] 2000 France Prospective 385 31 8.1 42 23
Oliver A et al. [19] 2000 Spain Prospective 37 6 16.2 50* 33
Radhakrishnan et al. [31] 2004 Canada Prospective 98 6 6.1 33 67
Levy I et al. [32] 2001-03 Israel Cross-sectional 186 42 22.6 31 14
Olivier KN et al. [33] 2002 USA Prospective 986 128 13.0 20 72
Roux AL et al. [34] 2004 France Prospective 1,582 104 6.6 48 22
Valenza et al. [35] 2006 Germany Prospective 60 8 13.3 50 50
Chalermskulrat W et al. [36] 2006 OH, USA Retrospective 132 26 19.7 46 50
Binder AM et al. [37] 2011 USA Registry 5,403 191 3.5 36 64
* =M. chelonae reported, but is here included as MABSC due to historical changes in taxonomy. § = percentage based on 6 chronic NTM cases.
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spontaneously [41] suggesting three phases of infection:
Transient, persistent and active. Why some patients
clear NTM suddenly without treatment, while others de-
teriorate rapidly warrants further investigation, as identi-
fying who and when to treat remains the clinician’s
central challenge in NTM management.Transmission
The first solid evidence of patient-to-patient transmis-
sion of NTM in a UK CF center was published in 2013
[15]. The authors used whole-genome sequencing and
showed, with a reasonable degree of certainty that the
MABSC subsp. massiliense had spread within their cen-
ter. Out of 31 patients nine shared one genetically near-
identical strain and two patients shared another strain.
A convincing case for in- and out-patient overlap as well
as careful elimination of potential sources of contamin-
ation (such as the water supply and bronchoscopy
equipment) was performed. The study thus confirms
suspicions raised in a report from Seattle, USA, that in-
dicated possible transmission of a single strain of M.
massiliense, identified through the use of pulse-field gel
electrophoresis and PCR [47] and a similar, but less cited
report from Sweden [48]. Mapping the genetic popula-
tion structure of MABSC is an urgent issue currently be-
ing examined by Floto et al. in a multicenter study. Thisis expected to have significant impact on how infection
control is managed in the in- and out-patient clinic.
Lung transplantation
The view that NTM constitute an absolute contraindica-
tion for lung transplantation is being modified [49,50].
Reports on outcome following lung transplantation in
CF patients with NTM infection are few and the impact
on mortality remains unknown, although increased mor-
bidity is consistently reported [49,51]. While aggressive
treatment is recommended [2], eradication prior to
transplantation is often unrealistic. Despite this, NTM dis-
ease does not preclude successful recovery after trans-
plantation and new recommendations are expected to
reflect this, bringing hope to a small, but growing number
of patients, in desperate need of lung transplantation.
Antibiotic treatment
Since the important shift in the 1990s away from antitu-
berculous regimes towards macrolide based multidrug
therapy [52], not much new has been accomplished in
the field of antibiotic treatment of NTM. A part from a
current phase 2 trial of inhaled amikacin in the US, a re-
cent Cochrane Review concluded, that not a single ran-
domized trial comparing antibiotic treatment of NTM
lung infection in CF has been completed [53]. NTM are
notoriously difficult to treat and require multidrug
Qvist et al. Respiratory Research 2014, 15:41 Page 4 of 6
http://respiratory-research.com/content/15/1/41treatment for 12 months or more. At present, ATS
guidelines are widely accepted as the standard of care
[2], but there are several ongoing controversies about
MAC and MABSC disease that could benefit from an
updated consensus. The superiority of one macrolide
over another has not been demonstrated for MAC lung
disease, nor has the benefit of routinely including an IV
drug (amikacin) early on been demonstrated [2] and
both issues remain undecided for newly diagnosed
MAC. A preliminary trial from a non-CF setting suggests
that a two-drug regimen of clarithromycin and etham-
butol may be non-inferior to the recommended three-
drug regimen, which today includes rifampicin [54].
The duration and intensity of antibiotic treatment for
MABSC, especially in patients that do not clear the bac-
teria, remains a headache for most clinicians. Inhaled
therapy is increasingly used in MABSC regimens and a
recent retrospective study of inhaled amikacin found
that while reductions in smear positivity and some
symptomatic improvement were observed, toxicity was
not uncommon [55]. Hopefully, preliminary results from
the ongoing phase 2 trial of inhaled liposomal amikacin
will be released in 2014. New CF specific treatment
guidelines under way are not expected to change the
fundamental structure of past MABSC recommenda-
tions, which consist of an initial induction phase
followed by long maintenance therapy, but new regi-
mens will likely include longer induction phases and
generally more antibiotics, with azithromycin as the
macrolide of choice. NTM specific drug-drug interac-
tions, medication side-effects and nonadherence are also
areas receiving fresh attention.
Conclusions
NTM seem to have found a successful niche in the
structurally complex and often antibiotic rich environ-
ment of the CF lung. The central paradigms of how pul-
monary NTM infection is initiated and how the disease
progresses and interacts with the host have all shifted
within the last years and upcoming consensus docu-
ments are eagerly awaited. While recent changes in the
understanding of NTM disease have reinvigorated the
field, the challenge remains, if such advances can be suc-
cessfully translated into improved management and care.
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